RxDoctor Payments DataLook up a doctor →

Abdul Wahab, MD

Nephrology · Falls Church, VANPI 1043230980

Payments from drug & device makers

$35,628in general payments, 2019–2025

Across 376 payments — averaging $94.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$28K
  • Mallinckrodt Hospital Products Inc.$836
  • AstraZeneca$708
  • Novo Nordisk$683
  • GSK$661
  • ANI Pharmaceuticals, Inc.$624
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$3751%
  • Speaking & faculty fees$25,57372%
  • Travel & lodging$1,3714%
  • Food & beverage$7,74022%
  • Education$5712%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,628 in reported general payments places this provider in the 85th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$241,266
Medicare patients
325
Services billed
1,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$81,383
MounjaroTirzepatide51$75,137
Synjardy XrEmpagliflozin/Metformin Hcl53$64,183
FarxigaDapagliflozin Propanediol60$56,980
EliquisApixaban30$40,714
RybelsusSemaglutide17$28,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$23,328
JanuviaSitagliptin Phosphate19$23,112
Tresiba Flextouch U-100Insulin Degludec31$23,111
TradjentaLinagliptin19$18,617
OzempicSemaglutide11$18,461
MyrbetriqMirabegron12$15,312
JanumetSitagliptin Phos/Metformin Hcl15$13,829
Sevelamer Carbonate25$3,583
Midodrine Hcl32$3,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$194$164,184149 claims
Lilly USA, LLCMounjaro$82$75,13751 claims
AstraZenecaFarxiga$708$56,98060 claims
Novo NordiskRybelsus, Ozempic$683$47,33628 claims
PfizerEliquis$27$40,71430 claims
MerckJanuvia, Janumet$319$36,94134 claims
GSKTrelegy Ellipta$661$23,32817 claims
Astellas Pharma US IncMyrbetriq$55$15,31212 claims
ANI Pharmaceuticals, Inc.Valsartan$624$1,18925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 298 nephrology providers in Virginia.

Other nephrology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →